Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hims & Hers Health Inc (NY: HIMS )

16.92 +0.61 (+3.74%)
Official Closing Price Updated: 7:00 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,794,626
Open 17.12
Bid (Size) 16.75 (1)
Ask (Size) 17.00 (4)
Prev. Close 16.31
Today's Range 16.63 - 17.19
52wk Range 5.650 - 25.74
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Hims & Hers To Offer Access To Compounded Diabetes And Weight Loss Drugs For Just $99/Month To Certain Professional Personnel
Hims & Hers Health will offer compounded GLP-1 weight-loss medications for as low as $99 per month to eligible U.S. military personnel, veterans, teachers, nurses, and first responders. The telehealth... 
Via Benzinga
Hims & Hers to Offer Access to Compounded GLP-1 Injections for as Low as $99/Month to U.S. Military, Veterans, Teachers, Nurses and First Responders
From Hims & Hers
Via Business Wire

Performance

YTD
+75.52%
+75.52%
1 Month
+2.36%
+2.36%
3 Month
-24.43%
-24.43%
6 Month
+1.14%
+1.14%
1 Year
+173.34%
+173.34%

More News

Read More
Hims & Hers Acquisition: How Innovation Will Flourish
Via The Motley Fool
How Is The Market Feeling About Hims & Hers Health?
Via Benzinga
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
Via The Motley Fool
Deep Dive Into Hims & Hers Health Stock: Analyst Perspectives (8 Ratings)
Via Benzinga
Is Hims & Hers Health Stock a Buy?
Via The Motley Fool
Hims & Hers Stock Pops After Massive Acquisition
Via The Motley Fool
Hims & Hers Health Stock Is Crashing: Should You Buy the Dip?
Via The Motley Fool
Is Hims & Hers Health the Next Teladoc?
Via The Motley Fool
Exposures COVID-19
Novo Nordisk Reports Positive Results Of Weight-Loss Drug Liraglutide For Children As Young As 6, Eyes FDA And EMA Approval
Via Benzinga
Exposures Product Safety
Invest While You Can: Pullbacks on These 3 Stocks Won’t Last Long
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Is Hims & Hers Health Stock a Buy?
Via The Motley Fool
Four Stocks To Watch This Week - Monday, Sept 9
Via Talk Markets
Battle Over Compounded Weight-Loss Medications - Sustainability and Regulation
Via Benzinga
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.
Via The Motley Fool
Got $1,000? 3 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
Billionaires Are Buying Hims & Hers Health Hand Over Fist. Should You Follow Their Lead?
Via The Motley Fool
2 No-Brainer Growth Stocks to Buy With $200 Right Now
Via The Motley Fool
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Why Hims & Hers Health Stock Was Falling This Week
Via The Motley Fool
Why Hims & Hers Stock Crashed on Tuesday
Via The Motley Fool
Why Hims & Hers Health Stock Is Falling
Via Benzinga
American Woodmark Reports Downbeat Results, Joins Snowflake And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.